Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children

European Journal of Medical Research

Volumn 10, Issue 12, 2005, Pages 503-508

  Funk, Markus B ^a   Notheis, G ^b   Schuster, T ^a   Elanjkal, Z ^a   von Hentig, N ^a   Sturmer M ^a   Linde, R ^a   Dunsch, D ^a   Konigs C ^a   Wintergerst, U ^b   Kreuz, W ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Children; Efavirenz; First line therapy; HIV; Plasma level; Viral load

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIVIRUS AGENT; DIDANOSINE PLUS STAVUDINE; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ARTHRALGIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LYMPHOCYTE COUNT; MALE; NEUROTOXICITY; NONHUMAN; OPEN STUDY; PERINATAL INFECTION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RASH; STEADY STATE; TREATMENT OUTCOME; VIRUS LOAD;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 29444439834     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Guidelines for the use of antiretroviral agents in pediatric HIV infection http://AIDSinfo.nih.gov - March, 2005
2. Staszewski S, Morales-Ramirez J, Tashima KT, et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006- Team. N Engl J Med 341(25): 1865-73
3. Starr SE, Fletcher CV, Spector SA, et al. (1999) Combination therapy with efavirenz, nelfinavir and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 341 (25): 1874- 81.
4. Funk MB, Linde R, Wintergerst U, et al. (1999) Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 13: 1653 - 58.
5. Paediatric European Network for Treatment of AIDS (PENTA). (2002) Comparison of dual nucleoside analogue reverse transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 359 (9308): 733-40.
6. Lainka E, Oezbek S, Falck M, et al. (2002) Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 110 (5): e56.
7. Starr SE, Fletcher CV, Spector SA, et al.; PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group. (2002) Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21(7): 659-63.
8. Verweel G, Sharland M, Lyall H, et al. (2003) Nevirapine use in HIV-1-infected children.AIDS 25; 17 (11): 1639-47.
9. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL; PACTG 356 Investigators. (2004) A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 350(24):2471-80.
10. van Leth F, Phanuphak P, Ruxrungtham K, et al. (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 (9417): 1253-63.
11. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. (2002) Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis. 185(8):1062-9.
12. Marzolini C, Telenti A, Decosterda LA, et al. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
13. Niehues T, Wintergerst U, Funk MB, et al. (2001) Empfehlung zur antireroviralen Therapie bei HIV-infizierten Kinder - Konsensusstatement der Pädiatrische Arbeitsgruppe AIDS (PAAD). Monatsschr Kinderheilk 149 (12): 1372 - 1382
14. Centers for Disease Control and Prevention: (1994) 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 43: 1 - 10.
15. Marzolini C, Telenti A, Buclin T, et al. (2000) Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Sci Appl. 740 (1): 43-58.
16. Shetty BV, Kosa MB, Khalil DA, et al. (1996) Preclinical pharmacokinetics and distribution to tissue of AG 1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 40: 110 - 4.
17. Sturmer M, Berger A, Preiser W. (2004) HIV-1 genotyping: comparison of two commercially available assays. Expert Rev Mol Diagn. 4(3):281-91.
18. Sturmer M, Berger A, Doerr HW. (2003) Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: Effects on sensitivity and complexity of the assay. J Med Virol. 71(4):475-479
19. Larder BA, Kohli A, Kellam P, et al. (1993) Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
20. Engelhorn C, Hoffmann F, Notheis G et al. (2002) Effect of antiretroviral combination therapies including efavirenz in heavily pre-treated HIV-infected children. Eur J Med Res 29; 7 (1): 30-4.
21. Brundage RC, Yong FH, Fenton T, et al. (2004) Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother. 48 (3): 979-84.
22. Bacheler L, Jeffrey S, Hanna G, et al. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing non-nucleoside reverse transcriptase inhibitor therapy. J Virol. Jun; 75 (11): 4999-5008.
23. Deeks SG. Nonnucleoside Reverse Transcriptase Inhibitor Resistance. (2001) JAIDS Mar; 26 (Suppl. 1): S25-S33.